CD274 and neoplasm: Currently, PD-L1 protein expression is the only approved biomarker for ICI in NSCLC in Europe, while tumour mutational burden (TMB) and microsatellite instability (MSI) are additionally approved by the FDA in an entity-agnostic manner.